Earnings Feed

Consumer

Consumer-facing investments increased 400 basis points for the full year, contributing to margin pressure but fueling growth.
Diluted EPS decreased 42% year-over-year, with Q4 EPS at $0.09 versus $0.64 last year.
Fiscal 2025 full year organic sales declined 8%, with nearly two-thirds of the decline from travel retail, which fell 28%.
Fourth quarter organic net sales declined 13%, with all categories down except fragrance, and travel retail as a primary driver.
Generated $1.3 billion net cash flow from operations in fiscal 2025, down from $2.4 billion prior year, impacted by lower earnings and restructuring payments.
Gross margin expanded 230 basis points to 74%, exceeding May outlook by 50 basis points despite volume deleverage.
Operating margin contracted 220 basis points to 8%, driven by sales declines and increased consumer-facing investments.
Recorded $425 million impairment charges in Q4 related to Dr.Jart+ and Too Faced due to underperformance in key markets.

ULTA

Consumer

Capital expenditures totaled $77 million, primarily for new and remodeled stores, with depreciation up 9% to $71 million.
Comparable sales grew 6.7%, driven by a 3.7% increase in transactions and a 2.9% increase in average ticket size.
Diluted earnings per share increased 9.1% to $5.78, including a $0.03 tax benefit from stock-based compensation.
Gross margin expanded by 90 basis points to 39.2%, aided by lower inventory shrink and merchandise margin expansion.
Inventory rose to $2.4 billion from $2 billion, reflecting new brand launches, store growth, and the Space NK acquisition.
Net sales increased 9.3% to $2.8 billion in Q2 2025 compared to $2.6 billion last year.
Operating profit rose 4.8% to $345 million, representing 12.4% of sales, down 50 basis points from 12.9% last year.
SG&A expenses increased 15% to $742 million, or 26.6% of sales, due to higher incentive compensation, payroll, and corporate overhead.